[Skip to Navigation]
[Skip to Navigation Landing]
Article
August 1987

Cyclophosphamide 'Pulses' in Chronic Progressive Multiple Sclerosis: A Preliminary Clinical Trial

Author Affiliations

From the Department of Neurology, Reed Neurological Research Center (Drs Myers and Ellison and Ms Frane), the Medical Immunology Laboratory, Center for Interdisciplinary Research and Immunologic Diseases, Department of Microbiology and Immunology (Drs Fahey and Moody), and the Department of Biostatistics (Dr Mickey), UCLA School of Medicine.

Arch Neurol. 1987;44(8):828-832. doi:10.1001/archneur.1987.00520200032014
Abstract

• To our knowledge, this is the first clinical trial in multiple sclerosis (MS) demonstrating the feasibility of directing immunomodulating therapy by monitoring immunologic results. Cyclophosphamide was administered at monthly intervals, escalating the dose until there was a significant reduction in both the number of blood B lymphocytes and helper/inducer (CD4) T cells of 14 patients with chronic progressive MS. The frequency and severity of adverse effects led us to conclude that the regimen is too toxic for the long-term treatment of patients with MS.

×